WO2016171640A8 - Биологически активное вещество полифармакологического действия растительного происхождения - Google Patents
Биологически активное вещество полифармакологического действия растительного происхождения Download PDFInfo
- Publication number
- WO2016171640A8 WO2016171640A8 PCT/UA2015/000101 UA2015000101W WO2016171640A8 WO 2016171640 A8 WO2016171640 A8 WO 2016171640A8 UA 2015000101 W UA2015000101 W UA 2015000101W WO 2016171640 A8 WO2016171640 A8 WO 2016171640A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavonoid
- effect
- virus
- rhamnazin
- tricin
- Prior art date
Links
- 229940088623 biologically active substance Drugs 0.000 title abstract 4
- 230000000694 effects Effects 0.000 title abstract 3
- -1 tricin flavonoid Chemical class 0.000 abstract 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 8
- 229930003935 flavonoid Natural products 0.000 abstract 7
- 235000017173 flavonoids Nutrition 0.000 abstract 7
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract 6
- 229930182486 flavonoid glycoside Natural products 0.000 abstract 6
- MYMGKIQXYXSRIJ-UHFFFAOYSA-N rhamnacene Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(OC)=C1 MYMGKIQXYXSRIJ-UHFFFAOYSA-N 0.000 abstract 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract 5
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract 5
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract 5
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 abstract 4
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract 4
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 abstract 4
- 235000008714 apigenin Nutrition 0.000 abstract 4
- 229940117893 apigenin Drugs 0.000 abstract 4
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 abstract 4
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 abstract 4
- 235000009498 luteolin Nutrition 0.000 abstract 4
- 229960001285 quercetin Drugs 0.000 abstract 4
- 235000005875 quercetin Nutrition 0.000 abstract 4
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 abstract 4
- 230000000840 anti-viral effect Effects 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 abstract 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 abstract 2
- 150000002215 flavonoids Chemical class 0.000 abstract 2
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 1
- 241000743799 Calamagrostis Species 0.000 abstract 1
- 241000744363 Deschampsia Species 0.000 abstract 1
- 241000196324 Embryophyta Species 0.000 abstract 1
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241000209504 Poaceae Species 0.000 abstract 1
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 235000013339 cereals Nutrition 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000007955 flavonoid glycosides Chemical class 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Изобретение относится к фармакологии и может использоваться для получения лекарственных средств для лечения и профилактики вирусных заболеваний, вызванных вирусами герпеса, гриппа, гепатитов В и С, а также вирусиндуцированных иммунодефицитов. Биологически активное вещество полифармакологического действия, полученное из зеленых частей и колосков злаковых растений семейства Gramineae, рода Calamagrostis Adans и / или рода Deshampsia Beauv, содержит флавоноиды, в частности, агликоны флавоноидов трицина (tricin), апигенина, лютеолина, кверцетина, рамназина и / или флавоноидные гликозиды трицина, апигенина, лютеолина, кверцетина, рамназина, вспомогательные вещества и имеет следующий состав, мас%: агликон флавоноида трицина и / или его флавоноидные гликозиды от 0,016 до 2,062%; агликон флавоноида апигенина и / или его флавоноидные гликозиды от 0,010 до 1,393%; агликон флавоноида лютеолина и / или его флавоноидные гликозиды от 0,01 до 4,979%; агликон флавоноида кверцетина и / или его флавоноидные гликозиды от 0,001 до 0,771%; агликон флавоноида рамназина и / или его флавоноидные гликозиды от 0,104 до 0,203%; вспомогательные вещества от 99,868 до 90,592%. Таким образом усовершенствование БАВ с определением конкретных составов действующих веществ БАВ, их физико-химических, биологических свойств приводит к изобретению его оптимального состава (Фиг.1) для антивирусного действия для конкретных вирусов, дозировок при создании лекарственных форм. Кроме того, определено, что БАВ является индуктором эндогенного интерферона типа (у), имеет апоптозмодулирующее действие, обладает антиоксидантными свойствами и повышает устойчивость клеток к свободнорадикальному стрессу. Антивирусное действие для конкретных вирусов определялось как антивирусное действие по отношению к вирусу простого герпеса типа 2, вирусу гриппа, вирусу бычьей диареи (вирусу гепатита С).
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/569,076 US20180133278A1 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
| EP15890050.6A EP3195872A4 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
| MX2017013696A MX2017013696A (es) | 2015-04-24 | 2015-10-28 | Sustancia biologicamente activa proveniente de una planta que tiene un efecto polifarmacologico. |
| BR112017021292-7A BR112017021292A2 (pt) | 2015-04-24 | 2015-10-28 | substância biologicamente ativa à base de plantas com efeito polifarmacológico |
| AU2015391981A AU2015391981B2 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
| CA2983299A CA2983299C (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
| EA201700340A EA033232B1 (ru) | 2015-04-24 | 2015-10-28 | Биологически активное вещество полифармакологического действия растительного происхождения |
| KR1020177032242A KR102461853B1 (ko) | 2015-04-24 | 2015-10-28 | 식물 기원의 다원 행동 생물학적 활성 물질 |
| CN201580079170.6A CN107530390A (zh) | 2015-04-24 | 2015-10-28 | 多药性作用植物生物活性物质 |
| US16/748,762 US20220000962A1 (en) | 2015-04-24 | 2020-01-21 | Plant-based biologically active substance having a polypharmacological effect |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201503915 | 2015-04-24 | ||
| UAA201503915 | 2015-04-24 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/569,076 A-371-Of-International US20180133278A1 (en) | 2015-04-24 | 2015-10-28 | Plant-based biologically active substance having a polypharmacological effect |
| US16/748,762 Division US20220000962A1 (en) | 2015-04-24 | 2020-01-21 | Plant-based biologically active substance having a polypharmacological effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016171640A1 WO2016171640A1 (ru) | 2016-10-27 |
| WO2016171640A8 true WO2016171640A8 (ru) | 2018-03-08 |
Family
ID=67998792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/UA2015/000101 WO2016171640A1 (ru) | 2015-04-24 | 2015-10-28 | Биологически активное вещество полифармакологического действия растительного происхождения |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20180133278A1 (ru) |
| EP (1) | EP3195872A4 (ru) |
| KR (1) | KR102461853B1 (ru) |
| CN (1) | CN107530390A (ru) |
| AU (1) | AU2015391981B2 (ru) |
| BR (1) | BR112017021292A2 (ru) |
| CA (1) | CA2983299C (ru) |
| EA (1) | EA033232B1 (ru) |
| MX (1) | MX2017013696A (ru) |
| WO (1) | WO2016171640A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| WO2018157081A1 (en) | 2017-02-27 | 2018-08-30 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2018170457A1 (en) | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2021262749A1 (en) * | 2020-06-26 | 2021-12-30 | Research Cancer Institute Of America | Compositions and methods for preventing and/or treating viral infection |
| CN113880898B (zh) * | 2020-10-30 | 2023-07-25 | 杭州拉林智能科技有限公司 | 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用 |
| CN114796016B (zh) * | 2022-05-31 | 2023-03-24 | 浙江伊瑟奇医药科技有限公司 | 一种私密修护精华液及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA54362C2 (en) * | 2002-12-26 | 2004-09-15 | Viktor Petrovych Atamaniuk | Method for isolating biologically active substance |
| DE102007054985A1 (de) * | 2007-11-17 | 2009-05-20 | Gerhard Dr. Sauermann | Topische Produkte zur Reduzierung der Häufigkeit von Rezidiven bei Lippenherpes |
| WO2009129818A1 (en) * | 2008-04-21 | 2009-10-29 | Herbonis Ag | Preparation and use of a plant extract from solanum glaucophyllum with an enriched content of 1,25-dihydroxyvitamin d3 glycosides and quercetin glycosides |
-
2015
- 2015-10-28 MX MX2017013696A patent/MX2017013696A/es unknown
- 2015-10-28 EA EA201700340A patent/EA033232B1/ru unknown
- 2015-10-28 EP EP15890050.6A patent/EP3195872A4/en active Pending
- 2015-10-28 KR KR1020177032242A patent/KR102461853B1/ko active IP Right Grant
- 2015-10-28 CA CA2983299A patent/CA2983299C/en active Active
- 2015-10-28 WO PCT/UA2015/000101 patent/WO2016171640A1/ru active Application Filing
- 2015-10-28 AU AU2015391981A patent/AU2015391981B2/en active Active
- 2015-10-28 US US15/569,076 patent/US20180133278A1/en not_active Abandoned
- 2015-10-28 BR BR112017021292-7A patent/BR112017021292A2/pt not_active IP Right Cessation
- 2015-10-28 CN CN201580079170.6A patent/CN107530390A/zh active Pending
-
2020
- 2020-01-21 US US16/748,762 patent/US20220000962A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015391981A1 (en) | 2017-11-30 |
| MX2017013696A (es) | 2019-07-29 |
| WO2016171640A1 (ru) | 2016-10-27 |
| KR20170139049A (ko) | 2017-12-18 |
| AU2015391981B2 (en) | 2021-08-19 |
| EP3195872A1 (en) | 2017-07-26 |
| BR112017021292A2 (pt) | 2018-12-04 |
| CN107530390A (zh) | 2018-01-02 |
| KR102461853B1 (ko) | 2022-10-31 |
| EP3195872A4 (en) | 2018-04-11 |
| US20180133278A1 (en) | 2018-05-17 |
| CA2983299C (en) | 2022-12-06 |
| EA033232B1 (ru) | 2019-09-30 |
| EA201700340A1 (ru) | 2017-10-31 |
| US20220000962A1 (en) | 2022-01-06 |
| CA2983299A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016171640A8 (ru) | Биологически активное вещество полифармакологического действия растительного происхождения | |
| Zandi et al. | In vitro antiviral activity of fisetin, rutin and naringenin against dengue virus type-2 | |
| WO2008036932A3 (en) | Compositions and methods comprising boswellia species | |
| Wan et al. | Baicalin inhibits TLR7/MYD88 signaling pathway activation to suppress lung inflammation in mice infected with influenza A virus | |
| Lawrence et al. | Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1β release in murine dendritic cells | |
| NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
| MX2009012299A (es) | Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue. | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| EA200870304A1 (ru) | Псевдоинфекционный флавивирус и его применение | |
| NO20053348L (no) | Farmasoytisk sammensetning for behandling av virusangrep. | |
| MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
| DE50112128D1 (de) | Retardpartikeldispersion | |
| MX2022002766A (es) | Vacunas contra el virus de la gripe y usos de las mismas. | |
| WO2011150320A3 (en) | Activators of innate immunity | |
| WO2004089983A3 (en) | Severe acute respiratory syndrome (sars) causing coronavirus | |
| WO2005063281A3 (de) | Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung | |
| George et al. | Antiviral activity of a standardized root water extract of Eurycoma longifolia (Physta®) against dengue virus. | |
| WO2009008924A3 (en) | Methods of preventing and treating viral infections by inhibiting the deisgylation activity of otu domain-containing viral proteins | |
| Macauslane et al. | Modulation of endoplasmic reticulum stress response pathways by respiratory viruses | |
| UA95299C2 (ru) | Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с | |
| MX2023008004A (es) | Derivado de adenosina y composicion farmaceutica que lo comprende. | |
| WO2005056051A3 (en) | Hepatitis b vaccines and compositions | |
| HUP0204209A2 (hu) | Készítmények lipidmetabolizmus-rendellenességek és allergiás formák megelőzésére és/vagy kezelésére | |
| KR101821181B1 (ko) | 항바이러스 기능을 가지는 복분자씨 추출물의 제조 방법 및 그 조성물 | |
| WO2018232174A3 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FLAVIVIRUS INFECTIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15890050 Country of ref document: EP Kind code of ref document: A1 |
|
| REEP | Request for entry into the european phase |
Ref document number: 2015890050 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201700340 Country of ref document: EA |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017021292 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 2983299 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 15569076 Country of ref document: US Ref document number: MX/A/2017/013696 Country of ref document: MX |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 20177032242 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2015391981 Country of ref document: AU Date of ref document: 20151028 Kind code of ref document: A |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017021292 Country of ref document: BR |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112017021292 Country of ref document: BR Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2477, SOLICITA-SE QUE A EXIGENCIA SEJA RESPONDIDA CORRETAMENTE, NUM PRAZO DE 60 DIAS, POR MEIO DA GRU DE CODIGO 207, ESPECIFICO PARA ESSE TIPO DE SERVICO. DEVE SER FEITO O PAGAMENTO DE DUAS GRUS 207, UMA REFERENTE A PUBLICACAO RPI 2477 E OUTRA REFERENTE A ESTE ADITAMENTO. |
|
| ENP | Entry into the national phase |
Ref document number: 112017021292 Country of ref document: BR Kind code of ref document: A2 Effective date: 20171004 |